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Summary
Background: Though the associations of CD14 with asthma have already been studied, the
results of different independent studies are in conﬂict, mostly due to differences in the
pathogenesis of varying asthma sub-phenotypes. The aim of our study was to perform an
association analysis of promoter single nucleotide polymorphism (SNP) –159C/T (rs2569190)
in the CD14 gene for Slovenian children with asthma.
Methods: We analyzed SNP –159C/T in a group of all asthmatics, and separately in a group
of atopic and non-atopic asthmatics. We also analyzed the inﬂuence of SNP –159C/T on
clinical parameters and the response to therapy with inhaled corticosteroids. We have
genotyped 247 children with asthma and a median age of 11 years (interquartile range,
5 years), and 158 healthy controls with a median age of 13 years (interquartile range, 5
years). We performed genotyping using a polymerase chain reaction (PCR) followed by
restriction fragment length polymorphism (RFLP) analysis.
Results: We found that SNP –159C/T in CD14 is not associated with asthma in Slovenian
children. However, non-atopic asthmatics with CT or TT genotypes have a lower FEV1/FVC
ratio as a measure of bronchial obstruction (87.4%, compared to 91.8% in patients
with the CC genotype, p = 0.017). Non-atopic asthmatics with CC or CT genotypes also
have increased bronchial hyperreactivity measured by PC20 of methacholine (0.41mg/ml,
compared to 1.50mg/ml in patients with a TT genotype, p = 0.018).
Conclusions: Our results suggest that CD14 is associated with asthma severity in Slovenian
children with non-atopic asthma.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Asthma is the most common serious chronic respiratory
disease of childhood and affects about 10% of children
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younger than 18 years of age.1 It is a complex, polygenic
disease and its pathogenesis cannot be explained by a single
mechanism or gene.2,3
Association studies for asthma focused primarily on
candidate genes that encode proteins for immune responses
or allergic inﬂammation.4,5 There is a considerable amount
of evidence linking asthma and atopy with genes located
on locus 5q31.6–8 The cytokine gene cluster located in the
5q31–33 region contains several potential candidate genes
for asthma, including interleukin (IL)-4, IL-5, IL-12B, IL-13
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and other genes, such as CD14.9 Evidence suggests that
this region is associated with airway hyperreactivity and the
severity of asthma.10–12
Two protein forms are encoded by the CD14 gene. One is a
surface antigen that is localized on monocytes, macrophages
and polymorphonuclear cells. It cooperates with other
proteins to mediate the innate immune response to bacterial
lipopolysaccharide (LPS) and other endotoxins. Another form
is soluble protein in blood serum.13,14
Numerous studies have found associations between
CD14 and either asthma, or its severity. Promoter single
nucleotide polymorphism (SNP) –159C/T in the CD14 gene
was ﬁrst investigated as a candidate SNP for atopy. Carriers
of –159T allele were found to have lower serum IgE
levels.15,16 Koppelman et al. ﬁrst reported the impact of
CD14 on asthma severity and identiﬁed the association
between SNP –159C/T and forced expiratory volume in the
ﬁrst second of expiration (FEV1).17 Kusunoki et al. found
higher levels of soluble CD14 in asthmatic children when
compared to controls.18 There has been a large number of
studies investigating the association of this SNP with asthma
risk, but the results have been very inconsistent.
The aim of our study was an association analysis of
the SNP –159C/T in the promoter of the CD14 gene
with asthma and asthma traits in Slovenian children. In
addition to previous studies, we analyzed the group of
atopic asthmatics and the group of non-atopic asthmatics
separately. Our study is the ﬁrst investigation of this SNP
for the Slovenian population. We have also analyzed the
inﬂuence of SNP –159C/T on clinical parameters and on the
response to therapy with inhaled corticosteroids in Slovenian
children with asthma. Also, we analyzed the inﬂuence of
a combination of CD14 and previously conﬁrmed asthma
candidate gene CTLA4 on asthma pathogenesis.19
Materials and methods
Patients and clinical measurements
Between January 1, 2007, and January 5, 2009, 247
asthmatic children with a median age of 11 years
(interquartile range, 5 years) were enrolled in this study.
All of the children had mild or moderate persistent asthma.
49.0% (n = 121) of them were treated at Pulmonary and
Allergic Outpatients, Department of Pediatric Medicine,
General Hospital Murska Sobota, and the other 51.0%
(n = 126) were treated at Pediatric Pulmonary Outpatients,
University medical centre Maribor. Asthma was diagnosed
according to the National Asthma Education and Prevention
Program (NAEPP) and American Thoracic Society (ATS)
criteria.20,21
All of the children treated in the outpatient clinic during
the period of study were included according to inclusion
and exclusion criteria. Patients with chronic inﬂammatory
diseases other than asthma and atopic diseases were
excluded from the study. Patients were free from any acute
diseases or asthma exacerbation at the time blood samples
were taken. Parents signed informed consent for children
younger than 15 years, while older children gave their own
informed consent. Genotype data from 158 non-atopic and
non-asthmatic Slovenians, with a median age of 13 years
(interquartile range, 5 years), and matched according to age
and gender, served as a control group.
The allergic status of asthmatics was determined with
both skin prick tests for the most common aeroallergens
(Allergopharma, Reinbek, Germany) and with speciﬁc
immunoglobulin E (IgE) measurements (CAP-RAST Pharmacia
& Upjohn, Freiburg, Germany).
Pulmonary function was measured with a Vitalograph 2150
spirometer (Compact, Buckingham, UK). For the purposes
of our study, the values of forced vital capacity (FVC) and
forced expiratory volume in the ﬁrst second of expiration
(FEV1) were recorded. We calculated the FEV1/FVC ratio
and used it as a measure of bronchial obstruction. FEV1
and FVC were expressed as a percentage of the predicted
normal value for gender, height and age.22 All patients
underwent spirometry before the treatment with inhaled
corticosteroids (ﬂuticasone dry powder; Flixotide Discus,
Glaxo); 121 of them repeated the test 4 weeks later. In these
121 patients the change in FEV1 was used as a measure of
response to antiasthmatic treatment.
Bronchial hyperresponsiveness was assessed with a metha-
choline bronchoprovocation test prior to the institution of
antiasthmatic treatment in all 247 patients. We calculated
a provocative concentration of methacholine (PC20) which
caused a FEV1 fall of 20% from the initial value.
We measured the fraction of exhaled nitric oxide (FENO)
before the institution of antiasthmatic treatment with a
Nixon analyzer (Aerocrine Inc., USA) in all 247 patients.
The analyzer uses a chemiluminescence method for gas
analysis.
A 12ml sample of blood was drawn from each patient
into EDTA tubes for genetic analysis and speciﬁc IgE
measurement. In 121 patients an eosinophil count and total
IgE were measured in the blood.
DNA extraction and genotyping
Whole blood from patients and controls was used for the
isolation of total genomic DNA. First, lymphocytes were
isolated using Ficoll-Paque Plus (GE Healthcare, Uppsala,
Sweden) according to the manufacturer’s instructions. Then,
using a TRI reagent (Sigma, Steinheim, Germany), DNA was
isolated and dissolved in water at ﬁnal concentration of
50 ng/ml.
Using bioinformatic tools we dimensioned primers (inter-
net application Primer3). Restriction enzyme was chosen
using the program Gene Runner. Genotyping of SNPs was
performed by polymerase chain reaction (PCR) followed by
restriction fragment length polymorphism (RFLP).
The PCR reaction was carried out in a 10-ml reaction
volume containing 50 ng of genomic DNA and 250 nM of each
oligonucleotide primer, 1.5mM MgCl2, 0.2mM dNTP mix,
10mM Tris-HCl and 0.5U Taq polymerase (Fermentas,
Vilinus, Lithuania). PCR conditions were as follows:
preincubation at 95ºC for 10min followed by 35 cycles of
1min denaturation at 95ºC, 30 s annealing at 64ºC, and
30 s extension at 72ºC for 5min. PCR products were digested
using restriction enzyme (Fermentas) at 37ºC overnight. The
PCR products were electrophoresed on 2% agarose gel and
visualized using ethidium bromide under UV ﬂuorescence.
Table 1 shows the optimal PCR conditions, appropriate
restriction enzyme, and the size of the PCR product before
and after restriction. Detection of PCR product is shown
in Fig. 1.
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Table 1
Conditions for PCR-RFLP reaction and fragment size after completion of test.
Primers Annealing temperature
Ta (ºC)
PCR product
size (bp)
Restriction
enzyme
Size of the product after
RFLP reaction (bp)
TTTCAGCGTGAGACCATTCA 64 561 BsuR I CC: 204+201+156
CCCCTAGGTCACAAGCGTAG 64 561 BsuR I TT: 360+201
Fig. 1. RFLP analysis of CD14 gene polymorphism –159C/T
(rs2569190).
Statistical analysis
Data analysis was carried out using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). Genotype and allele
frequencies were calculated for the patients and control
group. The c2 test and two-sided Fisher’s exact test were
used to calculate the signiﬁcance of the difference in
allele and genotype frequencies between asthmatics and
controls. We calculated the odds ratio (OR) for asthma
with 95% conﬁdence intervals (CI). With the t-test for two
independent samples we analyzed the inﬂuence of genotype
on clinical parameters which are normally distributed
quantitative traits: FEV1, FEV1/FVC ratio, blood eosinophil
count, total serum IgE, and the change in FEV1 after inhaled
corticosteroid treatment (dFEV1). With the Mann-Whitney
test we analyzed the inﬂuence of genotype on quantitative
traits which are not normally distributed: PC20 and FENO.
Distribution was determined by a Kolmogorov-Smirnov test
for groups larger than 50 individuals, or a Shapiro-Wilk test
for smaller groups. Gene-gene interaction was calculated
by logistic regression. In all tests p < 0.05 was considered to
indicate statistical signiﬁcance.
Results
Demographic data
In the entire group of asthmatics 57.1% (n = 141) were
male and 42.9% (n = 106) were female. The median age
was 11 years (interquartile range, 5 years). 64.0% of
patients (n = 158) were atopics and 30.8% of them (n = 76)
had non-atopic asthma. For 5.3% of patients (n = 13) the
asthma phenotype was not determined. Demographic data
and clinical characteristics of asthmatics are presented in
Table 2.
Association analysis
All studied populations were in Hardy-Weinberg equilibrium
with respect to –159C/T polymorphism. We compared the
allele and genotype frequencies of SNP –159C/T in each
group relative to control subjects, as it is summarized
in Table 3. In our study we did not ﬁnd any signiﬁcant
association of SNP –159C/T in the CD14 gene with asthma
or asthma phenotypes in Slovenian children.
Inﬂuence of SNP –159C/T on clinical parameters
We also analyzed the effect of the SNP –159C/T genotype
on clinical parameters. Statistical analysis was performed
ﬁrst by using the dominant model for the C allele, and then
by using the dominant model for the T allele. We found
the impact of SNP –159C/T (rs2569190) on some clinical
parameters important in asthma.
In the group of non-atopic asthmatics we found a
signiﬁcantly higher value of PC20 in subjects with the TT
genotype (1.50mg/ml), compared with heterozygotes and
CC homozygotes (0.41mg/ml, p = 0.018). The association of
the –159C/T genotype with the PC20 value was not conﬁrmed
in the group of all asthmatics or in patients with an atopic
asthma phenotype. Additionally, in non-atopic asthmatics,
SNP –159C/T inﬂuences the FEV1/FVC ratio. Individuals with
a CT or TT genotype have a lower FEV1/FVC ratio (87.4%)
compared to the CC genotype (91.8%, p = 0.017). We have
conﬁrmed this association by analyzing the allele effect in
non-atopic asthma patients. We found that carriers of the
Table 2
Clinical and laboratory parameters in all asthmatics.
Parameter N Minimum Maximum Mean Standard deviation
Age 247 5 19 11* 5#
FEV11 247 13 124 89.2 14.5
FEV12 121 42 126 91.6 14.2
dFEV1 121 -28 61 8.85 12.59
PC20(mg/ml) 247 0.02 8.0 0.29* 0.91#
FENO (ppb) 247 5 125 35* 46#
Total IgE (IU/ml) 121 2 3673 537.7 585.14
Eosinophils 121 40 1520 526.0 343.19
FEV11/FEV12: forced expiratory ﬂow in ﬁrst second before/after the treatment (in percent of
predicted for age, height and sex); dFEV1: change of FEV1 in 4 weeks of antiasthmatic therapy;
FENO: fraction of exhaled nitric oxide; Eosinophils: number of eosinophils in mm3 of blood.
*Median value; #Interquartile range.
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Table 3
Genotype and allele frequencies for SNP –159C/T in CD14 gene and statistical signiﬁcance
Genotype frequencies for SNP –159C/T (CD14 gene)
All asthmatics
n = 247 CC/CT+TT CC+CT/TT
Atopic asthmatics
n = 158 CC/CT+TT CC+CT/TT
Non-Atopic asthmatics
n = 76 CC/CT+TT CC+CT/TT
Controls
n = 158
CC: 33.2%
CT: 40.9%
TT: 25.9%
p = 0.66
OR = 0.90
(0.58–1.38)
p = 0.82
OR = 1.08
(0.68–1.70)
CC: 37.3%
CT: 34.2%
TT: 28.5%
p = 0.24
OR = 0.75
(0.50–1.19)
p = 0.48
OR = 1.23
(0.74–2.02)
CC: 27.6%
CT: 50.0%
TT: 22.4%
p = 0.65
OR = 1.17
(0.64–2.14)
p = 0.75
OR = 0.89
(0.46–1.70)
CC: 31.0%
CT: 44.3%
TT:24.7%
Allele frequencies for SNP –159C/T (CD14 gene)
All asthmatics
n = 247 C/T
Atopic asthmatics
n = 158 C/T
Non-atopic asthmatics
n = 76 C/T
Controls
n = 158
C: 53.6%
T: 46.4%
p = 0.94
OR = 0.98
(0.74–1.53)
C: 54.4%
T: 45.6%
p = 0.75
OR = 0.95
(0.70–1.30)
C: 52.6%
T: 47.4%
p = 0.92
OR = 1.02
(0.69–1.50)
C: 53.2%
T:46.8%
p: value calculated by chi-square test; n: number of individuals included in the analysis; OR: odds ratio, values in parentheses are
95% conﬁdence interval; CC: homozygote for allele C for SNP –159C/T; CT: heterozygote for SNP –159C/T; TT: homozygote for allele T for
SNP –159C/T.
Table 4
Association of SNP –159C/T (CD14 gene) and clinical parameters
All asthmatics
CC
(n = 82)
CT+TT
(n = 165)
p
Non-atopic asthmatics
CC
(n = 21)
CT+TT
(n = 55)
p
Atopic asthmatics
CC
(n = 59)
CT+TT
(n = 99)
p
PC20 (mg/ml) 0.40* 0.26* 0.502 0.40* 0.83* 0.231 0.40* 0.20* 0.445
FEV1/FVC 90.38 88.87 0.127 91.81 87.44 0.017 89.72 89.49 0.852
CC+CT
(n = 183)
TT
(n = 64)
p CC+CT
(n = 59)
TT
(n = 17)
p CC+CT
(n = 113)
TT
(n = 45)
p
PC20 (mg/ml) 0.32* 0.26* 0.791 0.41* 1.50* 0.018 0.25* 0.18* 0.320
FEV1/FVC 89.69 88.71 0.411 89.31 86.47 0.151 89.68 89.32 0.780
PC20: median concentration of methacholine which causes 20 % fall of forced expiratory volume in the ﬁrst second for each group;
FEV1/FVC: average measure of bronchial obstruction for each group; CC: homozygote for allele C for SNP –159C/T, CT: heterozygote for
SNP –159C/T, TT: homozygote for allele T for SNP –159C/T, n: number of individuals included in the analysis for each group, p: value
calculated by Mann-Whitney test for PC20 and Independent sample t-test for FEV1/FVC analysis.
*Values are represented as median value because of un-normal distribution of data.
T allele had a signiﬁcantly higher FEV1/FVC ratio (90.1%)
compared to carriers of allele C (87.8%, p = 0.038). We
have not conﬁrmed any inﬂuence of this SNP on the
concentration of total IgE, the eosinophil count, or the
effect of antiasthmatic therapy measured by a change in
FEV1. The most important results are shown in Table 4.
Combination of SNP –159C/T (CD14 gene) and SNP –60C/T
(CTLA4 gene)
In a previous study we found that polymorphism –60C/T in
the CTLA4 gene has an important role in response to therapy
with inhaled corticosteroids in asthmatic children.23 In the
present study we analyzed a combination of this SNP and
the –159C/T SNP in the CD14 gene. We found no signiﬁcant
effect of interaction between SNP –159C/T in CD14 or SNP
–60C/T in the CTLA4 gene on either asthma pathogenesis or
the clinical parameters.
Discussion
In this study we found that non-atopic asthmatics with a
CC genotype in SNP CD14 –159C/T (rs2569190) had higher
bronchial hyperreactivity, revealed by a lower PC20 value,
as compared to those with a TT genotype. The inﬂuence of
CD14 polymorphism on bronchial hyperreactivity has already
been studied in Polish and Korean children with asthma,
however no association has been found.24,25 Interestingly,
none of these studies analyzed asthma patients in separate
groups according to disease subphenotype. As we have
conﬁrmed an association between CD14 and bronchial
hyperreactivity only in non-atopic asthmatics, our data
suggest that genetic asthma association studies should be
performed separately for different asthma phenotypes.
In addition we discovered an association of SNP CD14
–159C/T with bronchial obstruction (FEV1/FVC ratio) in
children with non-atopic asthma. Carriers of the T allele in
this asthma phenotype have signiﬁcantly more pronounced
bronchial obstruction. This SNP has not been associated
with asthma severity in the Australian adult population.26
However, SNP +1437C/G in the same gene has already been
associated with asthma severity in Latino populations.27
Unfortunately, so far only a limited number of asthma
genetic studies have analyzed the potential correlation
between CD14 polymorphism and the clinical characteristics
of asthma patients.
Our results suggest fundamental differences in the
pathogenesis of asthma phenotypes. CD14 encodes the
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receptor for bacterial lipopolysaccharides (LPS) and SNP
CD14 –159C/T modulates cellular response to LPS and other
endotoxins.28 Exposure to endotoxins according to hygiene
hypothesis may prevent atopy and asthma.29 Therefore we
would expect instead an association with an atopic asthma
phenotype. Our results call for additional studies regarding
the role of CD14 in the response to viral infections which are
probably involved in non-atopic asthma pathogenesis.30 Our
results regarding the inﬂuence of SNP –159C/T on bronchial
obstruction and hyperreactivity are partially conﬂicting.
Carriers of the T allele in the non-atopic asthma group had
increased bronchial obstruction and diminished bronchial
hyperreactivity compared to carriers of the C allele.
These results most likely conﬁrm the hypothesis that the
mechanism of airway hyperreactivity, which is associated
with an asthma susceptibility locus at chromosome 5q31,
is nevertheless independent of asthmatic inﬂammation
or other asthma characteristics.6,31 In a linkage analysis
performed by Postma et al. bronchial hyperreactivity
was mapped to chromosome 5q31-q33. However, in this
study hyperreactivity has not correlated to atopy or other
asthma characteristics, which are supposed to be under the
control of additional genetic loci.6,29 We did not conﬁrm
CD14 polymorphism as a genetic risk factor for asthma
in the Slovenian population when comparing the allele
and genotype frequencies between controls and different
asthma groups, including atopics, non-atopics and asthma
patients as a whole group. Our data further conﬁrm the
heterogeneity in genetic risk factors for asthma and asthma
traits among different populations.
CD14 polymorphism was previously suggested as an
important genetic risk factor for asthma in Taiwanese32 and
Tunisian33 populations, and was suggested to play minor
role as genetic risk factor for asthma in Korean,25 Danish,34
Australian,26 Polish24 and German35 populations. Conﬂicting
results are probably due to differences in populations, and
also because of the differences in pathogenesis for different
asthma subphenotypes which were included in these studies
without the stratiﬁcation of the sample.
Our results suggest that polymorphism –159C/T in CD14
is not a major contributor or genetic risk factor for
childhood asthma in the Slovenian population but, rather,
inﬂuences the disease’s expression in children with non-
atopic asthma. In addition, our results provide additional
genetic data suggesting the different role of genes in atopic
and non-atopic asthma phenotypes and contribute to our
understanding of the asthma pathogenesis.
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